Two Kelun ADCs and two actinium-based radioconjugates start phase 1.
ApexOnco Front Page
Recent articles
Merck ditches vibostolimab and favezelimab following huge pivotal programmes.
The company impresses investors, but money’s running short.
Imlunestrant monotherapy only works in ESR1 mutants, but a Verzenio combo is better in all-comers.
AZD0486 seems highly active, including in patients relapsed on Car-T therapy.
Much has been made of anito-cel’s rivalry with Carvykti, but Arcellx reckons there’s plenty of market for both.
Inobrodib's first substantial multiple myeloma dataset suggests late-line promise.
Crossover scuppers Jaypirca's survival benefit, but full approval seems likely.
